ReviewChinese medicine2019
Novel drug delivery systems of Chinese medicine for the treatment of inflammatory bowel disease.
Review in Chinese medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 45 citations in OpenAlex.
- Article
- Dysregulated programmed cell death of intestinal epithelial cells in ulcerative colitis: Molecular mechanisms and novel therapeutic interventions (Review).International journal of molecular medicine · 2025Review
- Pingwei Powder alleviates high-fat diet-induced colonic inflammation by modulating microbial metabolites SCFAs.Frontiers in cellular and infection microbiology · 2025Article
- Nanotechnology-based Approaches for Targeted Drug Delivery to the Small Intestine: Advancements and Challenges.Current pharmaceutical design · 2025Review
- Commentary: Pingwei Powder alleviates high-fat diet-induced colonic inflammation by modulating microbial metabolites SCFAs.Frontiers in cellular and infection microbiology · 2025Article
- Optimal traditional Chinese medicine formulas in treating ulcerative colitis: Choose one or take it all?World journal of clinical cases · 2024Article
- Berberine-loaded PLGA nanoparticles alleviate ulcerative colitis by targeting IL-6/IL-6R axis.Journal of translational medicine · 2024Article
- Article
- Tectorigenin inhibits inflammatory responses in murine inflammatory bowel disease and LPS-stimulated macrophages via inactivating MAPK signaling pathway.Immunity, inflammation and disease · 2024Article
- Review
- Mechanochemical prepared ibuprofen-Drug delivery · 2022Article
- Targeted delivery of Chinese herb pair-based berberine/tannin acid self-assemblies for the treatment of ulcerative colitis.Journal of advanced research · 2022Article
- Huangqin Decoction Exerts Beneficial Effects on Rotenone-Induced Rat Model of Parkinson's Disease by Improving Mitochondrial Dysfunction and Alleviating Metabolic Abnormality of Mitochondria.Frontiers in aging neuroscience · 2022Article
- Apigenin-Mn(II) loaded hyaluronic acid nanoparticles for ulcerative colitis therapy in mice.Frontiers in chemistry · 2022Article
- New insights of engineering plant exosome-like nanovesicles as a nanoplatform for therapeutics and drug delivery.Extracellular vesicles and circulating nucleic acids · 2022Review
- Therapeutic potential of triptolide in autoimmune diseases and strategies to reduce its toxicity.Chinese medicine · 2021Review
- Oral colon-targeting core-shell microparticles loading curcumin for enhanced ulcerative colitis alleviating efficacy.Chinese medicine · 2021Article
- Receptor-mediated targeted drug delivery systems for treatment of inflammatory bowel disease: Opportunities and emerging strategies.Acta pharmaceutica Sinica. B · 2021Review
- Herbal Medicine, Gut Microbiota, and COVID-19.Frontiers in pharmacology · 2021Review
- A polysaccharide extract from the medicinal plant Maidong inhibits the IKK-NF-κB pathway and IL-1β-induced islet inflammation and increases insulin secretion.The Journal of biological chemistry · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel disease (IBD) is an idiopathic intestinal inflammatory disease that comprises ulcerative colitis (UC) and Crohn's disease (CD). IBD involves the ileum, rectum, and colon, and common clinical manifestations of IBD are diarrhea, abdominal pain, and even bloody stools. Currently, non-steroidal anti-inflammatory drugs, glucocorticoids, and immunosuppressive agents are used for the treatment of IBD, while their clinical application is severely limited due to unwanted side effects. Chinese medicine (CM) is appealing more and more attention and investigation for the treatment of IBD owing to the potent anti-inflammation pharmacological efficacy and high acceptance by patients. In recent years, novel drug delivery systems are introduced apace to encapsulate CM and many CM-derived active constituents in order to improve solubility, stability and targeting ability. In this review, advanced drug delivery systems developed in the past and present to deliver CM for the treatment of IBD are summarized and future directions are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.